New celecoxib derivatives as anti-inflammatory agents

Journal of Medicinal Chemistry

Volumn 51, Issue 1, 2008, Pages 142-147

  Szabó, György ^a   Fischer, János ^a   Kis Varga, Ágnes ^a   Gyires, Klára ^b  

^a GEDEON RICHTER LTD   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (5 TOLYL 3 TRIFLUOROMETHYLPYRAZOL 1 YL)BENZENESULFONYLAMINOOXY]PROPIONIC ACID; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; PARECOXIB; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; EDEMA; GASTROINTESTINAL SYMPTOM; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; STOMACH ULCER;

ACETIC ACID; ANIMALS; CARRAGEENAN; CHRONIC DISEASE; CRYSTALLIZATION; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; EDEMA; ETHANOL; GASTRIC MUCOSA; HYPERALGESIA; MALE; PYRAZOLES; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; STEREOISOMERISM; STOMACH ULCER; SULFONAMIDES;

EID: 37849035499     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070821f     Document Type: Article

References (24)

1. Xie, W.; Chipman, J. G.; Robertson, D. L.; Erikson, R. L.; Simmons, D. L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2692-2696.
2. Kujubu, D.A.; Fletcher, B. S.; Varnum, B. C.; Lim, R. W.; Herschman, H. R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 1991, 266, 12866-12872.
3. Hla, T.; Neilson, K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 7384-7388.
4. Hoffmann, C. COX-2 in brain and spinal cord - Implications for therapeutic use. Curr. Med. Chem. 2000, 11, 1113-1120.
5. Yoshida, S.; Ujiki, M.; Ding, X. Z.; Pelman, C.; Talamonti, M. S.; Bell, R. H.; Denham, W.; Adrian, T. E. Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs. Mol. Cancer 2005, 4, 27-35.
6. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromefnyl)-1H-pyrazol-1- yl]benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
7. Prasit, P.; Wang, Z.; Brideau, C.; Chan, C. C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O Neil, G. P.; Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I.; Tagari, P.; Therien, M.; Vickers, P.; Wong, E.; Xu, L. J.; Young, R. N.; Zamboni, R.; Boyce, S.; Rupniak, N.; Forrest, M.; Visco, D.; Patrick, D. The discovery of rofecoxib, [MK 966, VIOXX, 4-(4′- methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor. Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778.
8. Sorbera, L. A.; Castaner, R. M.; Silvestre, J.; Castaner, J. Etoricoxib: Analgesic drug, antiarthritic, cyclooxygenase-2 inhibitor. Drugs Future 2001, 26, 346-353.
9. Talley, J. J.; Brown, D. L.; Carter, J. S.; Graneto, M. J.; Kobolt, C. M.; Masferrer, J. L.; Perkins, W. E.; Rogers, R. S.; Shaffer, A. F.; Zhang, Y. Y.; Zweifel, B. S.; Seibert, K. J. 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A potent and selective inhibitor of COX-2. J. Med. Chem. 2000, 43, 775-777.
10. García-Rodriguez, L. A.; Hernández-Diaz, S. Nonsteroidal anti-inflammatory drugs as a trigger of clinical heart failure. Epidemiology 2003, 14, 240-246.
11. Whyte, W. B.; Faich, G.; Borer, J. S.; Makuch, R. W. Cardiovascular thrombotic events in arthritis trials of cyclooxygenase-2 inhibitor celecoxib. Am. J. Cardiol. 2003, 92, 411-8.
12. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Ferraz, M. B.; Hawkey, C. J.; Hochberg, M. C.; Kvien, T. K.; Schnitzer, T. J. for the VIGOR study group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 2000, 343, 1520-1528.
13. Mukherjee, P.; Nissen, S. E.; Topol, E. J. Risk of cardiovascular events associated with selective cox-2 inhibitors. JAMA, J. Am. Med. Assoc. 2001, 286, 954-959.
14. Fischer J.; Ganellin C. R. Analogue Based Drug Discovery; Wiley-VCH Verlag GmbH & Co. KGaA: New York, 2006.
15. Yuan, J. J.; Yang, D. C.; Zhang, J. Y.; Bible, R., Jr.; Karim, A.; Findlay, J. W. A. Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. Drug Metab. Dispos. 2002, 30, 1013-1021.
16. (a) Fischer J., Fodor, T.; Karpati, E.; Kis-Varga, I., Levai, S.; Erdelyi, P.; Zajerne, B. M.; Gere, A. New N-hydroxy-4-(3-phenyl-5- methylisoxazole-4-yl)benzenesulfonamide solvates, Patent WO2005/007620 A3, 2005.
17. (b) Erdelyi, P.; Fischer, J.; Gere, A.; Zajerne, B. M.; Kis-Varga, I. N-Hydroxy-valdecoxib monohydrate: An active metabolite and/or a pro-drug of Valdecoxib? Abstract of Papers, 19th International Symposium on Medicinal Chemistry (ISMC), Istanbul, Turkey, Aug 29-Sept 02, 2006; Poster 144.
18. (a) Szabó, Gy.; Fischer, J.; Kis-Varga, I.; Leibinger, J. New 1,2-diaryl pyrazoles useful as analgetic and anti-inflammatory agents, Patent WO2007/012906 A1, 2007.
19. (b) Szabó, Gy.; Fischer, J.; Kis-Varga, A.; Synthesis and Biological Investigation of New 1,2-Diaryl Heterocyclic Compounds as Anti-inflammatory Agents. Abstract of Papers,5th Joint Meeting on Medicinal Chemistry (JMMC), Portorož, Slovenia, June 17-21,2007; Poster 136.
20. Gierse, J. K.; Hauser, S. D.; Creely, D. P.; Koboldt, C. M.; Rangwala, S. H.; Isakson, P. C.; Seibert, K. Expression and selective inhibition of the constitutive and inductible forms of human cyclooxygenase. Biochem. J. 1995, 305, 479-484.
21. Hargreaves, K.; Dubner, R.; Brown, F.; Flores, C.; Joris, J. A. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32, 77-88.
22. Seibert, K.; Zhang, Y.; Leahy, K.; Hauser, S.; Masferrer, J.; Perkins, W.; Lee, L.; Isakson, P. Pharmacological and Biochemical Demonstration of the Role of Cyclooxygenase 2 in Inflammation and Pain. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 12013-12017.
23. Gyires, K. Morphine inhibits the ethanol-induced gastric damage in rats. Arch. Int. Pharmacodyn. Ther. 1990, 306, 170-181.
24. Okabe, S.; Takeuchi, K.; Murata, T.; Takagi, K. Effects of cimetidine and atropine sulfate in gastric secretion and healing of gastric and duodenal ulcers in rats. Eur. J. Pharmacol. 1977, 41, 205-208.